厄洛替尼联合贝伐珠单抗治疗携带活化EGFR突变的晚期非小细胞肺癌(BELIEF):国际多中心单臂2期试验
BELIEF是一项在8个欧洲国家29个中心开展的国际多中心单臂2期试验,纳入109例未经治疗、病理确诊的IIIB或IV期肺腺癌且携带活化EGFR突变(外显子19缺失或L858R突变)的患者,给予口服厄洛替尼150 mg每日一次联合静脉贝伐珠单抗15 mg/kg每21天一次,并按治疗前T790M状态分层。总体中位无进展生存期为13.2个月(95%CI 10.3-15.5),12个月无进展生存率55%(95%CI 45-64)。主要终点仅在T790M阳性亚组达到:T790M阳性组中位无进展生存期16.0个月(95%CI 12.7-不可估计),12个月无进展生存率68%(95%CI 50-81);T790M阴性组中位无进展生存期10.5个月(95%CI 9.4-14.2),12个月无进展生存率48%(95%CI 36-59)。安全性分析106例中5例发生4级不良事件(1例急性冠脉综合征、1例胆道感染、1例其他肿瘤、2例结肠穿孔),1例死于脓毒症。
要点
- T790M阳性组中位无进展生存期16.0个月(95%CI 12.7-不可估计),12个月无进展生存率68%(95%CI 50-81)。
- T790M阴性组中位无进展生存期10.5个月(95%CI 9.4-14.2),12个月无进展生存率48%(95%CI 36-59)。
- 总体中位无进展生存期13.2个月(95%CI 10.3-15.5),12个月无进展生存率55%(95%CI 45-64)。
- 安全性分析106例中5例发生4级不良事件,包括2例结肠穿孔、1例急性冠脉综合征、1例胆道感染、1例其他肿瘤,1例死于脓毒症。
- 主要终点仅在T790M阳性亚组达到,T790M阴性亚组未达到主要终点。
适用人群与场景
- 年龄18岁及以上、未经治疗、病理确诊的IIIB期或IV期肺腺癌患者,且经确认携带活化EGFR突变(外显子19缺失或L858R突变)。
诊断标准与关键阈值
- 活化EGFR突变定义为外显子19缺失或L858R突变,需经确认。
- 治疗前T790M耐药突变状态通过基于肽核酸探针的实时PCR集中检测确定,据此分为T790M阳性或阴性两个平行亚组。
处置流程与药物剂量
- 口服厄洛替尼150 mg每日一次,联合静脉贝伐珠单抗15 mg/kg每21天一次。
红旗征与不能漏的情况
- 4级不良事件包括急性冠脉综合征、胆道感染、其他肿瘤及结肠穿孔(2例),1例死于脓毒症。
研究设计与关键结果
- 研究类型:国际多中心单臂2期试验,在8个欧洲国家29个中心开展,纳入109例患者进行疗效分析,其中T790M阳性37例、阴性72例。
- 总体中位无进展生存期13.2个月(95%CI 10.3-15.5),12个月无进展生存率55%(95%CI 45-64)。
- 主要终点仅在亚组一(T790M阳性患者)达到:T790M阳性组中位无进展生存期16.0个月(95%CI 12.7-不可估计),12个月无进展生存率68%(95%CI 50-81);T790M阴性组中位无进展生存期10.5个月(95%CI 9.4-14.2),12个月无进展生存率48%(95%CI 36-59)。
- 安全性分析纳入106例,5例发生4级不良事件(1例急性冠脉综合征、1例胆道感染、1例其他肿瘤、2例结肠穿孔),1例死于脓毒症。
证据类型、等级与局限
- 证据类型:国际多中心单臂2期试验(BELIEF),ClinicalTrials.gov注册号NCT01562028。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,BELIEF试验为厄洛替尼联合贝伐珠单抗用于携带活化EGFR突变的非小细胞肺癌患者提供了进一步获益证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFR mutation in treatment-naive patients has been associated with a shorter progression-free survival to EGFR inhibition than in the absence of the T790M mutation. To test this hypothesis clinically, we developed a proof-of-concept study, in which patients with EGFR-mutant NSCLC were treated with the combination of erlotinib and bevacizumab, stratified by the presence of the pretreatment T790M mutation.
METHODS: BELIEF was an international, multicentre, single-arm, phase 2 trial done at 29 centres in eight European countries. Eligible patients were aged 18 years or older and had treatment-naive, pathologically confirmed stage IIIB or stage IV lung adenocarcinoma with a confirmed, activating EGFR mutation (exon 19 deletion or L858R mutation). Patients received oral erlotinib 150 mg per day and intravenous bevacizumab 15 mg/kg every 21 days and were tested centrally for the pretreatment T790M resistance mutation with a peptide nucleic acid probe-based real-time PCR. The primary endpoint was progression-free survival. The primary efficacy analysis was done in the intention-to-treat population and was stratified into two parallel substudies according to the centrally confirmed pretreatment T790M mutation status of enrolled patients (T790M positive or negative). The safety analysis was done in all patients that have received at least one dose of trial treatment. This trial was registered with ClinicalTrials.gov, number NCT01562028.
FINDINGS: Between June 11, 2012, and Oct 28, 2014, 109 patients were enrolled and included in the efficacy analysis. 37 patients were T790M mutation positive and 72 negative. The overall median progression-free survival was 13·2 months (95% CI 10·3-15·5), with a 12 month progression-free survival of 55% (95% CI 45-64). The primary endpoint was met only in substudy one (T790M-positive patients). In the T790M-positive group, median progression-free survival was 16·0 months (12·7 to not estimable), with a 12 month progression-free survival of 68% (50-81), whereas in the T790M-negative group, median progression-free survival was 10·5 months (9·4-14·2), with a 12 month progression-free survival of 48% (36-59). Of 106 patients included in the safety analysis, five had grade 4 adverse events (one acute coronary syndrome, one biliary tract infection, one other neoplasms, and two colonic perforations) and one died due to sepsis.
INTERPRETATION: The BELIEF trial provides further evidence of benefit for the combined use of erlotinib and bevacizumab in patients with NSCLC harbouring activating EGFR mutations.
FUNDING: European Thoracic Oncology Platform, Roche.
参考来源
- Rosell R, Dafni U, Felip E, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017. PMID: 28408243. doi:10.1016/S2213-2600(17)30129-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。